Lightnews — Scholar-powered news

Reposted by Paolo Tarantino, MD

Jame Abraham, MD, FACP @jameabraham.bsky.social · May 13

Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

2 2

Reposted by Paolo Tarantino, MD

OncLive @onclive.bsky.social · May 14

✨EXCLUSIVE PREVIEW: Ahead of the 2025 @ascocancer.bsky.social Annual Meeting, breast cancer experts highlight this year's most anticipated abstracts @stolaney1.bsky.social @ptarantinomd.bsky.social #ASCO25 #bcsm www.onclive.com/view/breast-...

1 3

Reposted by Paolo Tarantino, MD

OncoDaily @oncodaily.bsky.social · May 12

Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - Paolo Tarantino
@ptarantinomd.bsky.social
@stolaney1.bsky.social
@dfcibreastonc.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - OncoDaily

Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center / cancer, DFCI, OncoDaily, Oncology, Paolo Tarantino, Sara Tolaney

oncodaily.com

1 8

Reposted by Paolo Tarantino, MD

OncoDaily @oncodaily.bsky.social · May 13

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador
@ptarantinomd.bsky.social
@myesmo.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOBreast25 #ESMO

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador - OncoDaily

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador / Breast Cancer, cancer, ESMO, ESMO Ambassadors, ESMO Breast 25, OncoDaily, Oncology, Paolo

oncodaily.com

1 11

Reposted by Paolo Tarantino, MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 12

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf

1 4 6

Reposted by Paolo Tarantino, MD

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Apr 25

Congratulations to Drs. Paolo Tarantino, Caterina Sposetti, Pietro De Placido, and Tess O'Meara on receiving the prestigious #ConquerCancer #ASCO Merit Awards!
@ptarantinomd.bsky.social @csposettimd.bsky.social

2 5

Reposted by Paolo Tarantino, MD

Elizabeth McKenna @elizsmckenna.bsky.social · Apr 26

Don't miss "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development," a Cancer Discovery review by #AACR25 speakers Elisabeth de Vries and @raffcolo.bsky.social (along with Pat LoRusso & @ptarantinomd.bsky.social) doi.org/10.1158/2159...

3 4 15

Reposted by Paolo Tarantino, MD

OncoDaily @oncodaily.bsky.social · Apr 23

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer
@ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #BreastCancer

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer - OncoDaily

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer / Breast Cancer, cancer, Dana-Farber Cancer Institute, OncoDaily,

oncodaily.com

2 8

Reposted by Paolo Tarantino, MD

OncLive @onclive.bsky.social · Apr 21

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
@ptarantinomd.bsky.social @danafarbernews.bsky.social #BreastCancer
www.onclive.com/view/novel-a...

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment

Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.

www.onclive.com

1 3

Reposted by Paolo Tarantino, MD

OncoDaily @oncodaily.bsky.social · Mar 24

St. Gallen Consensus 2025 – 10 key votes - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#Cancer #Medicine #Health #BreastCancer #CancerConference #Oncology #OncoDaily

Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes - OncoDaily

Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes / Breast Cancer, breast oncology, cancer, Dana-Farber Cancer Institute, fight against cancer, G

oncodaily.com

1 9

Reposted by Paolo Tarantino, MD

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Mar 13

Register for the @OncLive Breast Cancer State of the Science Summit at the Hilton Boston in Back Bay on March 26th, hosted by Dr. Paolo Tarantino @ptarantinomd.bsky.social. All are free to attend including doctors, nurses, pharmacists, clinical researchers, etc.
👉 event.onclive.com/QVZ54b?RefId...

1 1

Reposted by Paolo Tarantino, MD

OncoDaily @oncodaily.bsky.social · Mar 11

A pleasure to join the gender balance session at JSMO25 - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/blog/253704

#Cancer #CancerResearch #Medicine #Health #JSMO25 #Oncology #OncoDaily

Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 - OncoDaily

Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 / cancer, JSMO25, OncoDaily, Oncology, Paolo Tarantino

oncodaily.com

1 8

Paolo Tarantino, MD @ptarantinomd.bsky.social · Feb 15

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.

Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

3 7

Reposted by Paolo Tarantino, MD

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Dec 17

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social

1 3 10

Reposted by Paolo Tarantino, MD

Julia Maués @itsnotpink.bsky.social · Dec 13

No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.)

For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.

Ilana Schlam @ilanaschlam.bsky.social · Dec 13

Wrapping up another fantastic #SABCS!

Amazing, practice-changing data were presented.

I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!

#SABCS24 @oncoalert.bsky.social

2 8 28

Reposted by Paolo Tarantino, MD

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · Dec 13

Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

9 18

Reposted by Paolo Tarantino, MD

Ilana Schlam @ilanaschlam.bsky.social · Dec 12

Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social

2 9

Reposted by Paolo Tarantino, MD

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · Dec 12

📌“Optimizing outcomes for HER2-expressing breast cancer through novel biomarkers and TKIs”
Great discussion by @ptarantinomd.bsky.social 👏🏻
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF @danafarber.bsky.social

2 6

Paolo Tarantino, MD @ptarantinomd.bsky.social · Dec 12

‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added!

For the impatient ones, press release here: www.businesswire.com/news/home/20...

If you’re in San Anyonio, though, make sure to attend the data presentation today by Otto Metzger!

2 16

Reposted by Paolo Tarantino, MD

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Dec 11

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will serve as a moderator in the #SABCS24 Educational Session 7. He will also give a presentation titled “Aiming for the Target: Increasing the Precision of #ADCs through Novel Biomarkers and Innovative Molecular Constructs”

2 7

Reposted by Paolo Tarantino, MD

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · Dec 11

📌Education Session: People's Choice -The Future in Antibody Drug Conjugates
Topic 1: “The ABC of ADCs: History, Mechanism of Action, Mechanisms of Resistance” by John Lambert 👏🏻
Moderator Introduction by @ptarantinomd.bsky.social 👏🏻
#SABCS24 #day2 @oncoalert.bsky.social #OncoAlertAF

4 10

Reposted by Paolo Tarantino, MD

Dana-Farber’s Breast Oncology Center @dfcibreastonc.bsky.social · Dec 11

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will be the invited discussant for Session 8: “Novel HER2 Therapeutics” at #SABCS24, his discussion will focus on #RadiationOncology.

🗓️ Thursday, December 12th
⏰ 7:30 - 7:45 am CST (8:30 – 8:45 am EST)
📍 Stars at Night 1-2

1 4

Paolo Tarantino, MD @ptarantinomd.bsky.social · Dec 11

Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?

4 13

Paolo Tarantino, MD @ptarantinomd.bsky.social · Dec 10

#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm

1 5